Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Afdhal,; Alam,; Ben-Ari,; Bredfeldt,; Brown,; Brown, Robert S.; Chung,; Darling,; Darling, Jama M.; Di Bisceglie,; Di Bisceglie, Adrian M.; Dickson,; Elbeshbeshy,; Everson,; Feld,; Feld, Jordan J.; Fenkel,; Frazier, Lynn M.; Fried,; Fried, Michael W.; Galati,; Gordon,; Harlan,; Hassan,; Hawkins,; Hinestrosa,; Jacobson,; Jacobson, Ira M.; Kerr,; Kuo,; Kuo, Alexander; Kwo,; Levitsky,; Lim,; Lim, Joseph K.; Lok,; Mailliard,; Manns,; Morelli,; Morelli, Giuseppe; Muir,; Nelson,; Nelson, David R.; O'Leary,; Pearlman,; Pockros,; Ramani,; Reau,; Reddy,; Reddy, K. Rajender; Schiff,; Sherman,; Shiffman,; Smith,; Spivey,; Sterling,; Stewart, Thomas G.; Sulkowski,; Sulkowski, Mark S.; Szabo,; Terrault,; Trautwein,; Vargas,; Watts,; Williams,; Zeuzem,

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Abstract

The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:rv0430198

Last time updated on 23/04/2020